For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Health Catalyst Inc (NASDAQ: HCAT) was $2.65 for the day, down -4.68% from the previous closing price of $2.78. In other words, the price has decreased by -$4.68 from its previous closing price. On the day, 0.71 million shares were traded. HCAT stock price reached its highest trading level at $2.805 during the session, while it also had its lowest trading level at $2.61.
Ratios:
Our analysis of HCAT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.81 and its Current Ratio is at 1.81. In the meantime, Its Debt-to-Equity ratio is 0.50 whereas as Long-Term Debt/Eq ratio is at 0.48.
Cantor Fitzgerald Downgraded its Overweight to Neutral on August 08, 2025, while the target price for the stock was maintained at $4.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 05 ’25 when Landry Benjamin sold 6,175 shares for $3.35 per share. The transaction valued at 20,705 led to the insider holds 141,812 shares of the business.
BENJAMIN LANDRY bought 6,175 shares of HCAT for $20,378 on Sep 05 ’25. On Sep 02 ’25, another insider, Linda Llewelyn, who serves as the Officer of the company, bought 2,854 shares for $3.36 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HCAT now has a Market Capitalization of 186490112 and an Enterprise Value of 261941104. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.59 while its Price-to-Book (P/B) ratio in mrq is 0.54. Its current Enterprise Value per Revenue stands at 0.829 whereas that against EBITDA is -14.631.
Stock Price History:
The Beta on a monthly basis for HCAT is 1.63, which has changed by -0.6780073 over the last 52 weeks, in comparison to a change of 0.118204355 over the same period for the S&P500. Over the past 52 weeks, HCAT has reached a high of $9.24, while it has fallen to a 52-week low of $2.52. The 50-Day Moving Average of the stock is -15.03%, while the 200-Day Moving Average is calculated to be -37.29%.
Shares Statistics:
HCAT traded an average of 716.90K shares per day over the past three months and 459870 shares per day over the past ten days. A total of 70.27M shares are outstanding, with a floating share count of 65.85M. Insiders hold about 6.42% of the company’s shares, while institutions hold 78.25% stake in the company. Shares short for HCAT as of 1759190400 were 6598072 with a Short Ratio of 9.20, compared to 1756425600 on 5251743. Therefore, it implies a Short% of Shares Outstanding of 6598072 and a Short% of Float of 10.69.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 8.0 analysts currently analyzing and rating the stock of Health Catalyst Inc (HCAT).The consensus estimate for the next quarter is $0.12, with high estimates of $0.16 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.62 and $0.16 for the fiscal current year, implying an average EPS of $0.26. EPS for the following year is $0.42, with 10.0 analysts recommending between $0.66 and $0.28.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 11 analysts. It ranges from a high estimate of $75.4M to a low estimate of $74.91M. As of. The current estimate, Health Catalyst Inc’s year-ago sales were $76.35MFor the next quarter, 11 analysts are estimating revenue of $74.79M. There is a high estimate of $75.26M for the next quarter, whereas the lowest estimate is $74.02M.
A total of 12 analysts have provided revenue estimates for HCAT’s current fiscal year. The highest revenue estimate was $335M, while the lowest revenue estimate was $309.55M, resulting in an average revenue estimate of $312.1M. In the same quarter a year ago, actual revenue was $306.58MBased on 12 analysts’ estimates, the company’s revenue will be $311.38M in the next fiscal year. The high estimate is $362.9M and the low estimate is $298.2M.
